Overview

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

Status:
Not yet recruiting
Trial end date:
2029-08-10
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the efficacy and safety of Baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age. The study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Follow-up period.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company